ADiTx Therapeutics, Inc.

The momentum for this stock is not very good. ADiTx Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in ADiTx Therapeutics, Inc..

News

Aditxt and Evofem amend merger agreement

Seeking Alpha - Healthcare Aditxt and Evofem amend merger agreement...\n more…

Aditxt, Evofem enter second amendment to plan of merger

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024

Business Wire Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), an innovation platform dedicated to accelerating health innovations, and womens health pioneer, Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem...\n more…

Aditxt files to sell $150M of common stock

SeekingAlpha.com: All News Aditxt (ADTX) filed a prospectus to sell $150M of common stock. This is not an offer to sell securities.\n more…

Aditxt files to sell $150M of common stock for holders

Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic Prostate Test, Targeting Early Detection in High-Risk Patients

Business Wire Aditxt, Inc. ('Aditxt') (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that its subsidiary, Pearsanta, Inc. (Pearsanta), has...\n more…